These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32203963)

  • 1. Impact of Age on Inflammation-Based Scores among Patients Diagnosed with Stage III Non-Small Cell Lung Cancer.
    Palomar-Abril V; Soria-Comes T; Tarazona Campos S; Martín Ureste M; Giner Bosch V; Maestu Maiques IC
    Oncology; 2020; 98(8):528-533. PubMed ID: 32203963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of diffuse cancer inflammation index (ALI), serum neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) in advanced-stage lung cancer.
    Ozturk AE; Komurcuoglu B; Karakurt GK; Ozturk O
    J Cancer Res Ther; 2024 Apr; 20(3):893-897. PubMed ID: 38102903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer.
    Shoji F; Kozuma Y; Toyokawa G; Yamazaki K; Takeo S
    Ann Thorac Cardiovasc Surg; 2020 Oct; 26(5):248-255. PubMed ID: 32074540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer.
    Kos FT; Hocazade C; Kos M; Uncu D; Karakas E; Dogan M; Uncu HG; Ozdemir N; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(9):3997-4002. PubMed ID: 25987075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
    Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
    Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
    Sert F; Cosgun G; Yalman D; Ozkok S
    Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?
    Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N
    Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
    Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
    Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases.
    Asano Y; Hayashi K; Takeuchi A; Kato S; Miwa S; Taniguchi Y; Okuda M; Matsumoto I; Yano S; Demura S
    Int Immunopharmacol; 2024 Jul; 136():112276. PubMed ID: 38820958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
    Fang Q; Yu J; Li W; Luo J; Deng Q; Chen B; He Y; Zhang J; Zhou C
    Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):178-190. PubMed ID: 36419356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of inflammatory parameters and nutritional index in clinical stage IVB endometrial carcinomas.
    Kiuchi K; Hasegawa K; Ochiai S; Motegi E; Kuno T; Kosaka N; Fukasawa I
    J Obstet Gynaecol; 2019 Feb; 39(2):237-241. PubMed ID: 30370797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.